The 340B effect: Making sense of prescription drug prices, policies and patient questions

Patients rarely ask their physicians about policy. They ask about what impacts them directly, like why their medication price changed, why the pharmacy says it needs approval again or why the same medicine looks different this month. Physicians and front office staff are the people expected to make sense of it. Patients also increasingly expect them to help address affordability, with 84% saying they want physicians to automatically select lower-cost medications when clinically appropriate. For both clinic staff and patients, the landscape feels like shifting sand under their feet.

The 340B program, which allows eligible hospitals and clinics to purchase certain outpatient drugs at discounted prices, often sits in the background of prescription costs. 340B does not change prices across the market for every prescriber. Instead, it changes the purchasing and reimbursement dynamics for certain covered entities, such as hospitals and clinics.

Physicians are often the first people patients turn to with questions about rising prescription costs linked to 340B policies. Independent physicians are on the front lines of the issue as they try to treat patients but face delays, access issues, administrative friction and a degraded patient experience.

Consider this example: An independent physician prescribes a drug to a patient but the patient encounters delays as coverage, sourcing or dispensing logistics are sorted out. The physician is then left to explain why the process changed to a patient who simply wants their medication at a cost they can afford.

Scale matters more than most physicians realize

One number puts 340B’s scale in context. In 2024, 340B-covered entities purchased $81.4 billion in drugs through the program, and that total wasn’t spread evenly. A set of 10 drugs, including oncology, multiple sclerosis and HIV therapies, accounted for $25.36 billion, roughly 30% of the total fund. These high-cost, high-need therapies are critical for patient survival, and when these costs fluctuate, the patients question the benefit, not the policy shift.

At that scale, even narrow policy changes influence how drug costs and incentives play out across sites of care. Recent court action over the proposed pilot shows how quickly changes can come, and why the consequences do not stop at the policy level.

The latest court decision highlights how quickly the rails can move

The U.S. Department of Health and Human Services (HHS) proposed a rebate-based pilot through the Health Resources and Services Administration (HRSA) to change how 340B discounts are delivered. Under the traditional 340B structure, eligible hospitals and clinics could receive a discount when purchasing a drug. Under the pilot program, they would have to pay more up front and seek the savings later through rebates.

The rationale for this pilot was that drug manufacturers were already advocating for a rebate system rather than the original up-front 340B discount. Ultimately, many hospital groups opposed the pilot program, arguing that it would impose a major operational and financial strain on covered entities and, as a result, HHS could not legally impose such changes. That opposition became a legal challenge in the federal courts.

Hospitals participating in 340B do not have to shift to a rebate-based model yet. The traditional up-front discount structure will stay in place unless, or until, HHS redesigns the program and it survives legal challenges.

For physicians, the takeaway is practical. Policy swings can change patient out-of-pocket expectations quickly, even when nothing about the clinical decision changes.

When patient costs shift without warning, physicians are left defending clinical decisions against a pricing experience they do not control. When the system feels arbitrary, patients start questioning whether a lower-cost option was chosen for cost reasons rather than clinical appropriateness.

Where physicians feel it in day-to-day practice

Physicians aren’t managing 340B directly during a 15-minute visit, nor are they policy makers. However, the program still influences the environment that their patients experience in the following ways:

• Patients raise questions about affordability earlier. Patients may ask for a cheaper alternative before they ask about side effects, especially after recent cost surprises. That anxiety can lead to delayed fills, requests to switch midcourse or early abandonment at the pharmacy counter.
• Prescribing gets constrained by practical access. Physicians aim to prescribe the simplest regimen that is safe and tolerable and offers the most ease in support of adherence for their patients. However, affordability and access pressures can push choices toward the easiest option to obtain, even when the preferred option differs clinically.
• Independent practices carry a greater share of the explanation load. Larger hospitals and practices often get paid significantly more for the same services, and that advantage adds up. These hospitals can then spread administrative work across dedicated financial navigation teams. Independent practices, however, don’t have this luxury. With limited front desk and back-office support, patients are more likely to leave the visit wondering why their cost went up, or why the rules changed again.

Because physicians cannot control those external pricing dynamics, practices that adopt a durability mindset can focus on drug savings that hold up even when policy and pricing rules change. That means reducing avoidable utilization and waste inside the pharmacy benefit using clinically familiar interventions that simplify regimens and decrease confusion for patients. This approach reduces friction for patients, lowers unnecessary spend and supports good clinical practice, without positioning physicians as responsible for policing prescription adherence or policy changes.

How waste patterns can be addressed without disrupting care

Here are four straightforward areas where practices can reduce waste without disrupting care, while clearly addressing patient concerns.

Address oversupply

The first step to ease patient concerns is to address oversupplying. Oversupply can occur when refills are filled too soon and medications accumulate, creating confusion, increasing the risk of improper use and driving avoidable spend.

Identify duplicative therapies

The next step is to identify duplicative therapies. This can happen across transitions of care, when multiple prescribers are involved or when treatment plans overlap. Identifying duplication can simplify regimens and reduce unnecessary costs.

Eliminate unnecessary medications

Lastly, physicians identify overlaps within drug classes that add expense without improving outcomes and deprescribe unnecessary medication. Reducing overlaps supports simplicity without sacrificing clinical intent, resulting in fewer side effects, fewer conflicting instructions and fewer moments of patient confusion about which medication to take.

Keep conversations clear

Patients can’t separate policy volatility from their lived experience. That helps explain why 68% do not trust prescription pricing outcomes. They feel the result through cost increases, medication confusion or treatment delay, and lack the support system to answer their concerns. When patients feel blindsided, trust takes a hit. Physicians can alleviate their concerns by keeping the conversation anchored in clarity.

For independent practices, this approach can help counter competitive pressure that arises when hospital systems operate under different financial dynamics. Durable savings tied to smarter utilization can be pursued alongside existing benefit strategies and without requiring changes to pharmacy benefit manager arrangements.

A steady path forward in a shifting system

As policies shift, physicians must expect regulatory changes and plan for them. When external mechanics shift fast, the best protection is a savings approach that does not depend on a specific discount structure.

Physicians do not need to resolve policy debates to help patients. The most practical step is to focus on affordability strategies that remain stable amid change, such as reducing avoidable utilization and waste, without disrupting care.

When the external rules change, physicians and practices feel the burn. Patients judge what they can see: whether or not their care still feels coherent. Simplifying regimens, eliminating duplication and reducing avoidable waste are practical ways to protect trust in a system that continues to move underneath them.

Josh Canavan, Pharm.D., is the head of pharmacy at RazorMetrics, where he oversees the company’s Pharmacy and Therapeutics Committee, which is responsible for the management and updating of the company’s Intervention Codex, a system of therapeutic alternatives. With a doctor of pharmacy degree from the University of Georgia, he has more than two decades of experience in both retail and hospital pharmacy, as well as in health care technology. He played a key role in developing EHR systems for rural hospitals before joining RazorMetrics in 2019.